IMI2 Project NeuroDeRisk: Neurotoxicity De-Risking in Preclinical Drug Discovery
Neurotoxicity, i.e., any adverse effect on the central nervous system or peripheral nervous system, is a major issue encountered in clinical phases of drug R&D that at the present stage of science and technology is still poorly predicted in the pre-clinical drug candidate assessment. As a part of the EU IMI2-RIA funded consortium NeuroDeRisk (Neurotoxicity De-Risking in Preclinical Drug Discovery) will provide novel validated and integrated tools for improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system, and thus help to de-risk drug candidates earlier in the R&D phases. Together with EFPIA members Sanofi, Novartis, MSD, Pfizer, UCB, Biopharma, AZ, Fujifilm Cellular Dynamics and a group of leading EU academic institutions, tPKPD will work evaluating pharmacokinetic aspects of the development of drug neurotoxicity.
For more details visit the web page: http://neuroderisk.eu/